Related Experiment Video

Updated: Apr 26, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

11.9K

Trial Watch: Toll-like receptor agonists in oncological indications

Fernando Aranda1, Erika Vacchelli1, Florine Obrist1

  • 1Gustave Roussy; Villejuif, France ; INSERM, UMRS1138; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France ; Université Paris-Sud/Paris XI; Paris, France.

Oncoimmunology
|August 2, 2014
PubMed

Insights

Toll-like receptor (TLR) agonists show promise in cancer immunotherapy by enhancing immune responses against tumors. Despite initial FDA approvals, clinical trial interest is shifting, prompting a re-evaluation of their evolving therapeutic potential.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptors (TLRs) are key innate immune sensors for pathogen and danger signals.
  • TLRs play a significant role in anticancer immunosurveillance and are targets for cancer immunotherapy.
  • Several TLR ligands have been investigated for their ability to enhance anti-tumor immune responses.

Purpose of the Study:

  • To summarize recent findings on the use of TLR agonists in cancer patients.
  • To discuss the evolution of clinical evaluation for TLR agonists in cancer therapy.
  • To provide an updated perspective on TLR agonist research and development in oncology.

Main Methods:

  • Review of recent clinical findings and trial data concerning TLR agonists in cancer.
  • Analysis of trends in clinical trial investigations of TLR agonists.
  • Comparative evaluation of FDA-approved and experimental TLR ligands.

Main Results:

  • Three TLR agonists (bacillus Calmette-Guérin, monophosphoryl lipid A, imiquimod) are FDA-approved for cancer treatment.
  • Despite approvals, there is a notable decrease in clinical trials evaluating TLR agonists.
  • This trend suggests a refocusing of interest towards alternative immunostimulatory agents in cancer therapy.

Conclusions:

  • TLR agonists have demonstrated therapeutic potential in cancer immunotherapy.
  • The declining number of clinical trials indicates a shift in research and development focus.
  • Continued evaluation of TLR agonists' evolving role in cancer treatment is warranted.
Keywords:
BCGCpG-7909Hiltonol™damage-associated molecular patternspolyI:Cresiquimod

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K